ArticleBMC biotechnology2025
Purification, characterization, and anti-cancer activity of methionine gamma-lyase from a native strain of Pseudomonas mosselii for human cancer treatment.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsMethionine gamma-lyase (MGL) specifically targets L-methionine-dependent cancer cells, making it a promising candidate for anti-cancer drug development. This study aims to purify and characterize L-methioninase from Pseudomonas mosselii and evaluate its potential anti-cancer properties. METHODS AND
resultsMGL was purified through heat treatment, ion exchange chromatography, and gel filtration, achieving a 6-fold purification and a 58.43% recovery rate. The enzyme displayed an activity of 61.16 U/mg and had a molecular weight of 48 kDa. Optimal activity was observed at a pH of 6 and temperatures ranging from 30 to 37℃. Kinetic studies revealed a Km value of 8.458 mM and a Vmax of 0.2702 U/mL/min for L-methionine. The anti-cancer effects of MGL were tested on MCF-7, MOLT-4, HepG-2, and U87MG cell lines. MTT assays demonstrated significant anti-cancer activity, inducing apoptosis in cancer cells while sparing normal fibroblasts. Real-time PCR results demonstrated decreased expression of BCL-2 and increased expression of caspase-3. This further confirms that apoptosis is enhanced by the use of gamma-lyase enzyme and methionine restriction in cancer cells.
conclusionsMGL shows promise as a targeted treatment for L-methionine-dependent cancers by selectively inducing apoptosis in cancer cells. Its specific action and effective purification establish MGL as a potential therapeutic candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.